Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. (Q53214880)

12 May 2018

title

Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. (English)

1 reference

12 May 2018

1 reference

Stephen McManus

1

1 reference

12 May 2018

Estelle Chamoux

series ordinal

2

1 reference

12 May 2018

Martine Bisson

series ordinal

3

1 reference

12 May 2018

Sophie Roux

series ordinal

4

1 reference

12 May 2018

publication date

1 February 2012

1 reference

12 May 2018

published in

Apoptosis

1 reference

12 May 2018

volume

17

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

121-131

1 reference

12 May 2018

Apoptosis in bone physiology and disease

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

TRAIL-induced signalling and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

New insights into apoptosis signaling by Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Life and death by death receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

TGF-β in cancer and bone: implications for treatment of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

High-throughput quantification of splicing isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Integrated genomic and proteomic analyses of gene expression in Mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Macrophage inflammatory protein-1α induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-β pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10495-011-0662-5

10.1007/S10495-011-0662-5

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018